HomeTrialNCT07168915
🔬NCT07168915Phase 1RECRUITING

A Study of V118E in Healthy Participants (V118E-003)

Study Summary

Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment126 participants
Primary Completion
Lead SponsorMerck Sharp & Dohme LLC
Data Retrieved2026-04-11 02:55:36.204956+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.